Iqvia enters pact with Argenx to provide safety systems, services

Iqvia (IQV) announced a strategic collaboration with Argenx (ARGX) to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance, or PV, safety services and solutions. Iqvia’s integrated PV services and technology platforms will support Argenx to enable efficient integration of safety data and adverse event identification and reporting, ultimately facilitating the delivery of new therapies to patients. The integration of safety data, operational processes and business acumen will support argenx to scale its PV and safety organization alongside future company growth. This builds on Iqvia and Argenx’s existing collaboration which focuses on the accelerated expansion of clinical development and commercialization of new indications.